Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2018 / Cilt: 23 - Sayı: 4

The Prevalence of Human Papillomavirus Genotypes in Women with Abnormal Cervical Cytology

Anormal Servikal Sitolojili Kadınlarda Human Papillomavirüs Genotiplerinin Prevalansı

Pages
186–192
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The most common genotype was HPV 16 in women with cervical precancerous lesions, and the diagnosis of oncogenic HPV genotypes is necessary to identify women at risk for cervical cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Human papillomavirus (HPV) is the major cause of cervical cancer, which is the second most common cancer in the world among women and is one of the major causes of cancer-related deaths in developing countries.
📊
Key Findings & Data:Approximately 500.000 new cervical cancers are identified each year in the world, and close to half of them are estimated to have resulted in death.
💡
Conclusion & Impact:Conclusion: The most common genotype was HPV 16 in women with cervical precancerous lesions, and the diagnosis of oncogenic HPV genotypes is necessary to identify women at risk for cervical cancer.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Human papillomavirus (HPV) is the major cause of cervical cancer, which is the second most common cancer in the world among women and is one of the major causes of cancer-related deaths in developing countries. Approximately 500.000 new cervical cancers are identified each year in the world, and close to half of them are estimated to have resulted in death. Cervical cancer is largely a preventable disease by early detection and treatment of cervical precancerous lesions with the combined use of high risk (HR) HPV DNA testing and cervical cytology test in cervical cancer screening. Prophylactic human papillomavirus vaccines, which provide primary protection against cervical cancer, have been started to be applied since 2006 with the aim of decreasing the incidence of cervical cancer and mortality. HPV vaccine has been proven to be effective in protecting against precancerous lesions by providing immunity against high risk (HR) HPV types and has been included in the routine vaccination program in many countries. The aim of this study was to investigate the prevalence and genotypes of HPV using real-time PCR test in women with abnormal cervical cytology. Materials and Methods: Between 2015-2017, a total of 315 women aged between 30 and 65 years were screened for HPV in the Clinic of Gynecology and Obstetrics, Faculty of Medicine, Cukurova University. Out of the 315 female cervical swabs, a total of 53 had abnormal cervical cytology and 262 had normal cervical cytology. HPV genotyping from cervical swab samples was performed by realtime PCR using Bosphore HPV Genotyping High Risk Kit v1 (Anatolia Geneworks, Turkey). Results: The prevalence of HPV infection in 53 women with abnormal cytology was 69.8% (n= 37) and 39.7% (n= 104) in the control group. The most prevalent HPV genotype among 37 HPV-positive women with abnormal cytology was HPV 16 (45.9%), followed by HPV 56 (18.9%), HPV 18 (16.2%) HPV 52 (13.5%), HPV 68 (13.5%), HPV33 (10.8%), HPV35 (10.8%), HPV 58 (10.8%), HPV 51(8.1%), HPV 39 (5.4%), HPV 45 (5.4%), and HPV 66 (5.4%). Among HPV-positive 104 women as the control group, the most common genotypes were HPV 16 (52.9%), HPV 18 (27.9%), HPV 45 (13.5%), HPV 56 (13.5%), HPV 68 (12.5%,) and HPV 52 (8.7%). Conclusion: The most common genotype was HPV 16 in women with cervical precancerous lesions, and the diagnosis of oncogenic HPV genotypes is necessary to identify women at risk for cervical cancer.

Özet

Giriş: Human papillomavirüs (HPV) servikal kanserin majör sebebidir. Servikal kanser kadınlar arasında dünya genelinde ikinci en sık görülen kanser olmakla birlikte, gelişmekte olan ülkelerde kansere bağlı ölümlerin önemli etkenlerinden biridir. Dünyada her yıl yaklaşık 500.000 yeni servikal kanser tanımlanmakta ve bunların yarısına yakınının ölümle sonuçlandığı tahmin edilmektedir. Servikal kanser taramasında yüksek riskli HPV DNA testi ve sitolojik tarama testinin birlikte kullanılmasıyla servikal prekanseröz lezyonların erken tanısı ve tedavisi sonucu servikal kanser büyük oranda önlenebilir bir hastalıktır. Servikal kansere karşı primer koruma sağlayan profilaktik HPV aşılarının 2006 yılından itibaren uygulanmaya başlanmasıyla servikal kanser sıklığı ve mortalitenin azalması amaçlanmıştır. HPV aşısının, yüksek risk (HR) HPV tiplerine karşı immünite gelişmesini sağlayarak prekanseröz lezyonlara karşı korunmada etkin olduğu ispatlanmış ve bu aşı birçok ülkede rutin aşı programına dahil edilmiştir. Bu çalışmada, anormal servikal sitolojili kadınlarda gerçek zamanlı polimeraz zincir reaksiyonu (PCR) testi kullanılarak HPV prevalansı ve genotiplerinin tespiti amaçlanmıştır. Materyal ve Metod: Çalışmaya, 2015-2017 yılları arasında Çukurova Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Polikliniğine başvuran yaşları 30-65 yıl arasında değişen, HPV taraması yapılan, 53’ü anormal servikal sitolojili ve 262’si normal servikal sitolojili toplam 315 kadına ait servikal sürüntü örneği dahil edilmiştir. Servikal sürüntü örneklerden HPV genotiplemesi HPV Genotipleme Testi Bosphore HPV Genotyping High Risk Kit v1 (Anatolia Geneworks, Turkey) kullanılarak gerçek zamanlı PCR testiyle gerçekleştirilmiştir. Bulgular: Anormal sitolojili 53 kadında HPV infeksiyonunun prevalansı %69.8 (n= 37), kontrol grubunda ise %39.7 (n= 104) idi. Anormal sitolojili HPV pozitif 37 kadında en baskın HPV genotipi HPV 16 (%45.9) olup bunu HPV 56 (%18.9), HPV 18 (%16.2), HPV 52 (%13.5), HPV 68 (%13.5), HPV 33 (%10.8), HPV 35 (%10.8), HPV 58 (%10.8), HPV 51 (%8.1), HPV 39 (%5.4), HPV 45 (%5.4) ve HPV 66 (%5.4) izlemiştir. Kontrol grubunda HPV pozitif 104 kadın arasında en yaygın genotiplerin HPV 16 (%52.9), HPV 18 (%27.9), HPV 45 (%13.5), HPV 56 (%13.5), HPV 68 (%12.5) ve HPV 52 (%8.7) olduğu görülmüştür. Sonuç: Servikal prekanseröz lezyonu olan kadınlarda en baskın genotip HPV 16 olup servikal kanser için risk altındaki kadınların tespitinde onkojenik HPV genotiplerinin tanısı gereklidir

🔖

Cite This Article

ÖZEN, S., ÇİMENTEPE, M., VARDAR, M. A., GÜMÜRDÜLÜ, D., YARKIN, F. (2018). The Prevalence of Human Papillomavirus Genotypes in Women with Abnormal Cervical Cytology. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 23 - Sayı: 4, 186–192. https://ajindex.com/articles/224457

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Araldi RP, Assaf SMR, Carvalho RF, Carvalho MACR, Souza JM, Magnelli RF, et al. Papillomaviruses: a systematic review. Genet Mol Biol 2017;40(1):1-21. McBride AA. Oncogenic human papillomaviruses. Philos Trans R Soc Lond B Biol Sci 2017;372(1732):20160273. Zhang L, Bi Q, Deng H, Xu J, Chen J, Zhang M, et al. Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: genotype-specific prevalence and attribution. BMC Infect Dis 2017;17(1):107. Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses 2017;9(8):E229. Ciavattini A, Clemente N, Tsiroglou D, Sopracordevole F, Serri M, Delli Carpini G, et al. Follow up in women with biopsy diagnosis of cervical low-grade squamous intraepithelial lesion (LSIL): how long should it be? Arch Gynecol Obste 2017;295(4):997-1003.
  2. Açikgöz A, Ergör G. Cervical cancer risk levels in Turkey and complianc to the national cervical cancer screening standard. Asian Pac J Cancer Prev 2011;12(4):923-7.
  3. Özmen V, Dağoğlu N, Dede İ, Akçakaya A, Kerem M, Göksel F, et al. Turkish ministry of health, 2nd Turkish medical general assembly clinical oncology study group report. J Breast Health 2016;12(1):9-17.
  4. Tabora N, Bulnes R, Toro LA, Claros JM, Massuger LF, Quint WG, et al. Human papillomavirus infection in Honduran women with cervical intraepithelial neoplasia or cervical cancer. J Low Genit Tract Dis 2011;15(1):48-53.
  5. Baskaran K, Kumar PK, Karunanithi S, Sethupathy S, Thamaraiselvi B, Swaruparani S. Detection of high-risk human papillomaviruses in the prevention of cervical cancer in india. Asian Pac J Cancer Prev 2015;16(18):8187-90.
  6. Zoa Assoumou S, Ndjoyi Mbiguino A, Mabika Mabika B, Nguizi Ogoula S, El Mzibri M, Khattabi A, et al. Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities. Infect Agent Cancer 2016;11:2. Kim CJ, Jeong JK, Park M, Park TS, Park TC, Namkoong SE, et al. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions. Gynecol Oncol 2003;89(2):210-7.
  7. Simanaviciene V, Gudleviciene Z, Popendikyte V, Dekaminaviciute D, Stumbryte A, Rubinaite V, et al. Studies on the prevalence of oncogenic HPV types among lithuanian women with cervical pathology. J Med Virol 2015;87(3):461-71.
  8. Correnti M, Medina F, Cavazza ME, Rennola A, Avila M, Fernándes A. Human papillomavirus (HPV) type distribution in cervical carcinoma, low-grade, and high-grade squamous intr